山东威高骨科材料股份有限公司2025年第三次临时股东会决议公告

Group 1 - The company held its third extraordinary general meeting of shareholders on December 29, 2025, in Shanghai, with no resolutions being rejected [2] - The meeting was convened by the board of directors and conducted in accordance with the Company Law and the company's articles of association, utilizing both on-site and online voting methods [2][3] - The meeting was attended by 7 out of 8 current directors, with the board secretary and other executives present, while one independent director was absent due to work commitments [3] Group 2 - A key resolution passed during the meeting was regarding the change of certain fundraising projects and the acquisition of equity in Suzhou Jiesibai Medical Technology Co., Ltd., which was approved [4] - The voting for the resolutions was conducted as ordinary resolutions, requiring more than half of the voting shares represented at the meeting to pass [5] Group 3 - The company signed a tripartite supervision agreement for the storage of raised funds, ensuring effective management and protection of investor rights [7][11] - The company was approved to publicly issue 41.4142 million shares at a price of RMB 36.22 per share, raising a total of RMB 1.5 billion, with a net amount of RMB 1.382 billion after deducting issuance costs [8][9] - A special account for the raised funds was established, which is exclusively for the storage and use of funds related to the acquisition and capital increase project [10][12] Group 4 - The tripartite agreement involves the company, China Agricultural Bank, and Huatai United Securities, outlining the management and supervision of the raised funds [12] - The agreement stipulates that any withdrawal exceeding RMB 50 million or 20% of the net raised funds must be reported to the supervising party [14] - The agreement will remain effective until all funds are fully utilized and the account is legally closed [15]